Workflow
东吴证券
icon
Search documents
经观月度观察|经济修复平稳 政策加力支持中小企业发展
Jing Ji Guan Cha Bao· 2026-01-23 15:12
Core Insights - The macroeconomic data for December 2025 indicates a stable recovery, with rising prices in non-ferrous metals, a manufacturing PMI returning to expansion, and growth in medium to long-term corporate loans [1] Economic Indicators - **CPI**: The Consumer Price Index (CPI) increased from 0.7% to 0.8% year-on-year, with food prices showing a 0.3% month-on-month increase and a 1.1% year-on-year increase [3] - **PPI**: The Producer Price Index (PPI) improved from -2.2% to -1.9% year-on-year, driven by rising prices in non-ferrous metals, which saw a 24.0% increase in mining and a 10.8% increase in smelting and processing [4] - **PMI**: The Manufacturing Purchasing Managers' Index (PMI) rose from 49.2% to 50.1%, indicating a return to expansion for large enterprises, while small enterprises remain in contraction [5] - **Fixed Investment**: Total fixed asset investment decreased by 3.8%, with real estate investment down by 17.2%, while equipment renewal investment grew by 11.8% [6] - **Credit Growth**: New RMB loans totaled 910 billion yuan, with medium to long-term corporate loans increasing significantly [7][8] - **M2 Growth**: The M2 money supply growth rate increased to 8.5%, up from 8.0%, indicating a rebound in liquidity [8]
华安国企机遇混合A:2025年第四季度利润88.15万元 净值增长率8.88%
Sou Hu Cai Jing· 2026-01-23 08:17
AI基金华安国企机遇混合A(018806)披露2025年四季报,第四季度基金利润88.15万元,加权平均基金份额本期利润0.1235元。报告期内,基金净值增长率 为8.88%,截至四季度末,基金规模为1067.76万元。 该基金属于偏股混合型基金。截至1月22日,单位净值为1.585元。基金经理是孙澍,目前管理的3只基金近一年均为正收益。其中,截至1月22日,华安国企 机遇混合A近一年复权单位净值增长率最高,达37.45%;华安双核驱动混合A最低,为36.45%。 基金管理人在四季报中表示,本基金在报告期内继续减持涨幅已经相对较大的有色金属板块,增持了部分化工、出行、消费行业的个股,继续持有非银和造 船等我们看好且估值没有被透支的板块。四季度在海外流动性宽松的预期下,有色金属出现了大幅的上涨,虽然上市公司的业绩在前三个季度有了大幅提 升,但是估值也已经上涨到了比较高的水平,至此我们前期看好该板块的逻辑和收益都已经兑现,再往后看价格的波动已经比较难以把握。 截至1月22日,华安国企机遇混合A近三个月复权单位净值增长率为9.06%,位于同类可比基金342/689;近半年复权单位净值增长率为26.26%,位于同类可 ...
研报掘金丨东吴证券:维持佛燃能源“买入”评级,业务多元发展业绩超预期
Ge Long Hui A P P· 2026-01-23 06:31
Core Viewpoint - Dongwu Securities report indicates that Fuan Energy's diversified business development has exceeded expectations, ensuring shareholder returns [1] Financial Performance - The company is projected to achieve a net profit attributable to shareholders of 1.001 billion yuan in 2025, representing a year-on-year growth of 17.3% [1] - In Q4 2025, the net profit attributable to shareholders is expected to reach 510 million yuan, showing a year-on-year increase of 30.6%, surpassing previous expectations [1] - The profit forecasts for 2025-2027 have been revised upwards to 1.001 billion, 1.070 billion, and 1.117 billion yuan respectively, from the original estimates of 872 million, 922 million, and 976 million yuan [1] Dividend Policy - The company plans to maintain a dividend payout ratio of no less than 65% for the years 2025-2027, ensuring returns for shareholders [1] Business Strategy - The company adheres to an "Energy + Technology + Supply Chain" strategy, focusing on urban natural gas operations while actively advancing in petrochemical products, hydrogen energy, thermal energy, photovoltaics, and energy storage [1] - Continuous efforts are being made in technology research and development, equipment manufacturing, supply chain operations, and other extended businesses [1] Market Outlook - The natural gas business is expected to develop steadily, while new energy, supply chain, extended, and technology R&D and manufacturing businesses are flourishing [1] - The rating for the company is maintained at "Buy" [1]
潍柴动力午后涨超5% GEV此前上修燃气轮机产能指引 行业景气度受益AIDC发展上行
Zhi Tong Cai Jing· 2026-01-23 05:55
Core Viewpoint - Weichai Power (000338) shares rose over 5% due to strong order growth and an accelerated production capacity plan in the gas turbine industry [1] Group 1: Company Performance - Weichai Power's stock increased by 5.08%, reaching HKD 25.6, with a trading volume of HKD 545 million [1] - GEV has advanced its target for annual gas turbine production capacity from 20 GW by Q3 2026 to H1 2026, and further raised its expansion plan to 24 GW by 2028 [1] Group 2: Industry Outlook - GEV plans to invest USD 10 billion in capital expenditures from 2025 to 2028 to support the increased production capacity [1] - The gas turbine industry is expected to experience a new upward cycle due to the accelerating construction of AI data centers, which is increasing electricity demand and requiring reliable power sources [1] - The market for gas turbines has significant replacement potential, benefiting domestic equipment manufacturers [1] Group 3: Market Opportunities - Changjiang Securities noted that Weichai Power is actively expanding its business in backup diesel engines for data centers and solid oxide fuel cells (SOFC) [1] - The large-cylinder business is entering a rapid growth phase, with performance consistently meeting expectations [1] - SOFC has strong overseas demand, and the company has secured intention orders, with large-scale production expected by 2027, indicating substantial future growth potential [1]
研报掘金丨东吴证券:维持捷昌驱动“买入”评级,机器人零部件深化布局
Ge Long Hui A P P· 2026-01-23 05:25
Core Viewpoint - The company, Jiechang Drive, has exceeded market expectations in its 2025 performance forecast, with a focus on deepening its layout in the robotics components sector [1] Group 1: Company Performance - Jiechang Drive is a leader in the linear drive industry, with subsidiaries in multiple global locations and five major production bases in Ningbo, Xinchang, Malaysia, the United States, and Europe [1] - The first phase of the European logistics and production base has been completed, enhancing collaboration with its German subsidiary and Austrian LOGICDATA, which will improve technology research and development, production delivery, and supply chain management capabilities in Europe [1] - The company has established an efficient customer demand response mechanism, effectively increasing customer satisfaction and loyalty, leading to a rise in market share and steady growth in linear drive control business [1] Group 2: Future Outlook - For 2026, the company expects its linear drive business revenue to maintain a steady year-on-year growth of 20-30% [1] - The company is developing its own robotics components product line, creating a second growth curve [1] - Due to the ongoing deepening of its overseas layout and stable performance growth, the company has revised its net profit forecasts for 2025-2027 to 416 million, 545 million, and 712 million yuan respectively, representing year-on-year increases of 47%, 31%, and 31% [1] - The current price corresponds to a PE ratio of 36x, 27x, and 21x for the years 2025, 2026, and 2027, respectively, maintaining a "buy" rating [1]
东吴证券:维持康宁杰瑞制药-B“买入”评级 核心管线上市申报中
Zhi Tong Cai Jing· 2026-01-23 02:37
Core Viewpoint - Dongwu Securities maintains a "Buy" rating for Corning Jereh Pharmaceutical-B (09966), anticipating multiple ADC pipelines to complete preclinical development by 2025, leading to adjustments in R&D expense forecasts and net profit estimates for 2025-2027 [1] Group 1: Pipeline Developments - The company has submitted a listing application for KN026, a HER2 bispecific monoclonal antibody, which is expected to receive approval by the end of 2026 or in 2027 [1] - JSKN003, the company's first ADC pipeline, is expected to submit a domestic listing application for HER2-positive breast cancer in 2026, with promising efficacy data presented at the 2025 ESMO conference for ovarian and colorectal cancers [2] Group 2: Clinical Progress and Efficacy Data - For JSKN003, the objective response rate (ORR) for platinum-resistant ovarian cancer patients was 32.0%, with a disease control rate (DCR) of 72.0%, and a median progression-free survival (PFS) of 4.1 months [2] - In colorectal cancer patients, JSKN003 achieved an ORR of 71.0%, a DCR of 100%, a median duration of response (DoR) of 9.89 months, and a median PFS of 11.04 months [2] Group 3: R&D Platform and Future Prospects - The company's self-developed platform continues to yield new pipelines, with the PD-L1/ITGB6/8 multifunctional ADC JSKN022 starting Phase I clinical trials in October 2025, and the PD-L1/VEGFR2 dual-target ADC JSKN027 having received IND approval in December 2025, with Phase I trials expected in 2026 [3]
东吴证券:维持康宁杰瑞制药-B(09966)“买入”评级 核心管线上市申报中
智通财经网· 2026-01-23 02:36
Core Viewpoint - Dongwu Securities maintains a "Buy" rating for Kangning Jereh Pharmaceutical-B (09966), anticipating multiple ADC pipelines to complete preclinical development by 2025, leading to adjustments in R&D expense forecasts and net profit estimates for 2025-2027 [1] Group 1: Financial Projections - The forecast for net profit attributable to the parent company is adjusted to -115 million yuan for 2025 and -97 million yuan for 2026, down from 14 million yuan and 63 million yuan respectively; a new forecast for 2027 is set at -26 million yuan [1] - The company is expected to gradually reduce losses as products like KN026 are anticipated to be launched domestically, with JSKN003 also nearing its application for market approval [1] Group 2: Product Pipeline Developments - KN026, a HER2 bispecific monoclonal antibody, has had its application for marketing approval accepted by NMPA, with expectations for approval by the end of 2026 or in 2027; the domestic rights have been granted to CSPC Pharmaceutical Group, while the company retains exclusive production rights [1] - JSKN003, the company's first ADC pipeline, is expected to submit a domestic application for HER2-positive breast cancer in 2026, with promising efficacy data presented at the 2025 ESMO conference for ovarian and colorectal cancers [2] Group 3: Research and Development Advancements - The company's self-developed platform continues to yield new pipelines, with the PD-L1/ITGB6/8 multifunctional ADC JSKN022 showing superior internalization efficiency and cytotoxic activity, having initiated Phase I clinical trials in October 2025 [3] - The PD-L1/VEGFR2 bispecific ADC JSKN027 has integrated multiple mechanisms and has received acceptance for its IND application, with Phase I clinical trials expected to commence in 2026 [3] - Additional ADCs, such as EGFR/HER3 bispecific dual-load ADC JSKN021, are anticipated to enter clinical development stages [3]
AI语音厂商思必驰重启IPO,辅导券商为东吴证券
Xin Lang Cai Jing· 2026-01-23 02:24
1月22日,AI语音厂商思必驰科技股份有限公司在江苏证监局办理辅导备案登记,拟首次公开发行股票 并上市,辅导券商为东吴证券。 ...
证券从业人员,数量跌破33万!四类人才紧俏
券商中国· 2026-01-23 01:17
2025年证券从业人员数量跌破33万人,同比减少近8000人。 过去三年,全行业有近3万名从业者离场,主要业务岗位的人才结构也随之发生调整。在业内人士看来,这背 后原因是行业价值锚点的变化。 国金证券人力资源部相关人士表示,人员结构的"有增有减",实际上是行业底层逻辑发生变革:人才的价值正 从过去的"关系与牌照驱动"转向未来的"专业与服务驱动"。 券商中国记者通过多方调研,试图厘清三大问题:从业者为何选择离开?行业对人才价值的要求发生了哪些变 化?考核机制如何适配证券行业新的发展理念?这些问题的答案,勾勒出证券公司与从业者在转型关键期面临 的发展抉择。 "人海战术"退潮 新一届国考面试名单近期公布,含调剂在内,证监会相关岗位共有近1100人入围面试。值得注意的是,2025年 证监会系统录用的公务员中,来自证券行业的从业人员占比明显提升。 通过"考公"转换职业赛道,是证券行业人才流动的路径之一。过去一年,证券行业人才职业选择多元:既有履 历亮眼的保代转任上市公司董秘,也有光鲜的卖方分析师跳槽至买方,更有行业明星试水知识付费成为网红, 还有从业者转行投身教培、餐饮、保险等领域。 当行业从高速扩张转向高质量发展,从 ...
美债市场高位盘整:PCE数据强化通胀压力 投资者重新审视“暂停降息”预期
Sou Hu Cai Jing· 2026-01-22 23:52
Group 1 - The U.S. Treasury market is experiencing volatility near five-month highs, reflecting cautious investor sentiment amid strong economic data and signals of a "pause" in interest rate cuts from the Federal Reserve [1] - On January 22, 2025, the yields on various maturities of U.S. Treasuries showed mixed movements, with the 2-year yield rising by 2.98 basis points to 3.608%, and the 10-year yield increasing by 0.6 basis points to 4.245% [1] - The yield curve is flattening, with the spread between the 2-year and 10-year Treasury yields narrowing by approximately 1.548 basis points to 63.881 basis points [1] Group 2 - The core Personal Consumption Expenditures (PCE) price index for Q3 2025 was reported at an annualized rate of 2.9%, aligning with market expectations, which supports the high yields in the Treasury market [2] - Federal Reserve officials, including those from Chicago, Kansas City, and San Francisco, have indicated a willingness to pause interest rate cuts in the upcoming meeting, citing a stable labor market and persistent inflation pressures [2] - Market expectations for the Fed to maintain interest rates in January are high, with a 95% probability according to the CME FedWatch tool [2] Group 3 - Global financial institutions are reassessing future policy paths and economic outlooks, with Dongwu Securities suggesting that a combination of looser fiscal and monetary policies could lead the U.S. economy to expand again by 2026 [2] - Continued investment in artificial intelligence (AI) is expected to be a significant driver of economic growth, although it may also pose upward risks to inflation from the demand side [2] - Everbright Securities predicts that the yield curve for U.S. Treasuries may continue to steepen in 2026, with a clear path for interest rate cuts potentially lowering short-term yields while concerns over tariffs and fiscal sustainability keep long-term yields elevated [2]